Top Ten most popular articles on Pharmafile.com this week

pharmafile | January 20, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten 

It’s Friday, and there have been some big revelations for the pharma industry this week. Brexit, the ever-present hot topic has surged back to prominence and has taken centre stage in discussions between industry figures. There’s bad news for some of the industry’s big players between record fines and facility closures, and don’t miss Janssen’s VP of Process Sciences Mauricio Futran’s discussion on the benefits of continuous production.

10. Lilly three strikes in three years not out in Teva patent challenge

Eli Lilly has successfully won its patent case against Teva Pharmaceuticals, with the case being decided at the US Court of Appeals. The case was regarded Lilly’s third biggest selling drug, Alimta, a treatment used in patients suffering from non-small cell lung cancer (NSCLC) and mesothelioma.

9. New NICE ultra-rare disease proposals “not fit for purpose”, says BIA

The BioIndustry Association (BIA) has accused new proposals put forward by the NICE of being “not fit for purpose” and potentially denying patients from accessing treatments for ultra-rare disease.

8. J&J to reveal drug price increases next month

Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase its transparency with patients.

7. 22 pharma companies join forces for global non-communicable disease initiative

Access Accelerated is a global initiative consisting of over 20 partners including Pfizer, GSK, J&J, Roche, Novartis and more to improve access to preventative measures against non-communicable disease.

6. SMC rejects Janssen’s multiple myeloma treatment Darzalex

The Scottish Medicines Consortium has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma.

5. Merck in $230 million swoop for Vertex cancer programmes

Merck has completed a deal with Boston-based biotech firm Vertex Pharmaceuticals for the rights to four cancer programmes worth $230 million.

4. Daiichi pulls out of India with closure of 170-strong R&D plant

Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in its global restructuring programme.

3. Advancing the Pharmaceutical Supply Chain

Mauricio Futran, vice president, Process Sciences, Janssen Supply Chain, discusses, in the latest issue of Pharmafile, Janssen’s move into continuous production and the benefits attained through the move.

2. Shire fined $350 million in largest-ever bribery case of its kind

Shire is accused of bribing clinicians and physicians by using kickbacks to encourage the use of Dermagraft, a diabetic foot ulcer treatment.

1. PM May announces Brexit plan, BioIndustry Association CEO reacts

Theresa May has finally announced the first inklings of the government’s Brexit plan in a speech on Tuesday; BIA CEO Steve Bates gives his thoughts on the matter.

Related Content


Top Ten most popular articles on Pharmafile.com this week

As the year winds to a close, excitement is rising around the efficacy and availability …


Top Ten most popular articles on Pharmafile.com this week

The top ten news stories this week focus on herd immunity, as the Director of …


Pharmafile.com’s weekly COVID-19 news round-up

The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …

Latest content